Implant ComplicationNCT05729607
Vertical Soft Tissue Augmentation With CTG vs ADM
A study testing Vertical soft tissue augmentation in people with Implant Complication, run by Harvard Medical School (HMS and HSDM) at 1 site in United States.
Trial summary
The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative Read more about this study
- Who is it for?
- Ages 18 to 99 yearsHealthy volunteers can take part
- Conditions the study is for
- Implant Complication
- What is being tested?
- Vertical soft tissue augmentation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 28 participants
- Where
- 1 siteUnited States
- Study dates
- 26 May 2023to 27 Nov 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Periodontally and systemically healthy
- Full-mouth plaque score and full-mouth bleeding score ≤ 20% (measured at four sites per tooth)
- Presence of single functional dental implant in the anterior with a PSTD
- Implants diagnosed as healthy (Berglundh et al., 2018)
Who cannot join
- Contraindications for surgery
- Systemic condition (e.g. diabetes mellitus, HIV, cancer, etc) that could compromise wound healing
- Patients pregnant or attempting to get pregnant (self-reported)
- Untreated periodontitis
- Untreated peri-implant mucositis or peri-implantitis (Berglundh et al., 2018)
- Smoking, defined as self-reported daily habit. Occasional smokers won't be excluded
- History of soft tissue grafting at the implant site within the last 6 months
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Harvard School of Dental Medicine
Boston, Massachusetts, 02115
Lorenzo Tavelli, DDS, MS, 7346044364, lorenzo_tavelli@hsdm.harvard.edu
About this study
Official title: Vertical Soft Tissue Augmentation With Dermal Matrix and Enamel Matrix Derivative vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences in the Esthetic Zone: A Randomized, Controlled, Clinical, Trial
The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative
Read the detailed description
The present randomized clinical trial aims at investigating two approaches (autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative) when performed for vertical soft tissue augmentation at sites with peri-implant soft tissue dehiscences. Clinical, volumetric, ultrasonographic, and patient-reported outcomes will be evaluated at different time points up to 1 year.
- Conditions
- Implant Complication
- Being tested
- Vertical soft tissue augmentation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vertical soft tissue augmentationProcedure or surgery
Vertical soft tissue augmentation with autogenous connective tissue graft (CTG)
Vertical soft tissue augmentationProcedure or surgery
Vertical soft tissue augmentation with acellular dermal matrix (ADM) and enamel matrix derivative (EMD)
| Study group | Role | What they receive |
|---|---|---|
| Connective tissue graft | Active comparator | Autogenous connective tissue graft harvested from the palate as a free gingival graft and then de-epithelialized Receives: Procedure: Vertical soft tissue augmentation |
| Dermal matrix + EMD | Experimental | Acellular dermal matrix and enamel matrix derivative Receives: Procedure: Vertical soft tissue augmentation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Soft tissue dehiscence depth
Change of the depth of the Soft tissue dehiscence (vertical measurement of the complication, in relation to the level of the cemento-enamel junction of the contralateral homologous tooth) at 12 months compared to baseline (expressed in millimeters)
Measured: 12 months
Secondary outcomes (6)
Complete peri-implant soft tissue dehiscence (PSTD) coverage
Percentage of cases with complete resolution of the implant esthetic complication (expressed as a percentage)
Measured: 12 months
mean peri-implant soft tissue dehiscence (PSTD) coverage
Percentage of coverage of the soft tissue dehiscence compared to baseline, measured with a formula considering final PSTD depth and initial PSTD depth (expressed as a percentage)
Measured: 12 months
Mucosal thickness changes
Changes within the mucosal thickness measured with ultrasonography (expressed in mm)
Measured: 3, 6, and 12 months
3D Volumetric changes
Changes within the buccal contour measured by superimposing digital impressions obtained with optical scanning (expressed in mm^3)
Measured: 3, 6, and 12 months
Post-operative pain
Patient-reported pain after the surgical procedure (expressed with a 0-10 visual analogue scale [VAS])
Measured: 14 days after the surgery
Professional esthetic assessment (IDES)
Esthetic outcomes of the treatment assessed by a calibrated operator using the Implant soft tissue Dehiscence coverage Esthetic Score (IDES) (expressed using points, based on the IDES classification system from Zucchelli et al. 2021) The range is from 0 (worst outcome) to 10 (best outcome)
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Feb 2023
- Study start26 May 2023
- Primary completion27 Feb 2027 (estimated)
- Study completion27 Nov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Implant ComplicationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Parallel-arm
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 28 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Harvard Medical School (HMS and HSDM)
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lorenzo Tavelli, Harvard Medical School (HMS and HSDM)
- Investigators
- Lorenzo Tavelli, DDS, MS, Principal investigator, Harvard School of Dental Medicine, Boston, USA
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05729607
- Sponsor's protocol ID
- ITI IMP (22-0600)
- Status last verified
- Sep 2025
- First submitted
- 6 Feb 2023
- Last updated
- 18 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vertical Soft Tissue Augmentation With Dermal Matrix and Enamel Matrix Derivative vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences in the Esthetic Zone: A Randomized, Controlled, Clinical, Trial
- ClinicalTrials.gov ID
- NCT05729607
- Acronym / sponsor ID
- ITI IMP (22-0600)
- Conditions
- Implant Complication
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 28 participants (estimated)
- Lead sponsor
- Harvard Medical School (HMS and HSDM)University, hospital or other
- Study start
- 26 May 2023 (actual)
- Primary completion
- 27 Feb 2027 (estimated)
- Study completion
- 27 Nov 2027 (estimated)
- First posted
- 15 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative
Detailed description
The present randomized clinical trial aims at investigating two approaches (autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative) when performed for vertical soft tissue augmentation at sites with peri-implant soft tissue dehiscences. Clinical, volumetric, ultrasonographic, and patient-reported outcomes will be evaluated at different time points up to 1 year.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Parallel-arm
| Arm | Type | Receives |
|---|---|---|
| Connective tissue graft | Active comparator | Procedure: Vertical soft tissue augmentationAutogenous connective tissue graft harvested from the palate as a free gingival graft and then de-epithelialized |
| Dermal matrix + EMD | Experimental | Procedure: Vertical soft tissue augmentationAcellular dermal matrix and enamel matrix derivative |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age ≥ 18 years
- Periodontally and systemically healthy
- Full-mouth plaque score and full-mouth bleeding score ≤ 20% (measured at four sites per tooth)
- Presence of single functional dental implant in the anterior with a PSTD
- Implants diagnosed as healthy (Berglundh et al., 2018)
Key exclusion criteria (7 listed)
- Contraindications for surgery
- Systemic condition (e.g. diabetes mellitus, HIV, cancer, etc) that could compromise wound healing
- Patients pregnant or attempting to get pregnant (self-reported)
- Untreated periodontitis
- Untreated peri-implant mucositis or peri-implantitis (Berglundh et al., 2018)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vertical soft tissue augmentationVertical soft tissue augmentation with autogenous connective tissue graft (CTG) | Procedure or surgery | Connective tissue graft |
| Vertical soft tissue augmentationVertical soft tissue augmentation with acellular dermal matrix (ADM) and enamel matrix derivative (EMD) | Procedure or surgery | Dermal matrix + EMD |
Primary outcome
Change in Soft tissue dehiscence depth
Time frame: 12 months
Change of the depth of the Soft tissue dehiscence (vertical measurement of the complication, in relation to the level of the cemento-enamel junction of the contralateral homologous tooth) at 12 months compared to baseline (expressed in millimeters)
6 secondary outcomes
Complete peri-implant soft tissue dehiscence (PSTD) coverage
Time frame: 12 months
mean peri-implant soft tissue dehiscence (PSTD) coverage
Time frame: 12 months
Mucosal thickness changes
Time frame: 3, 6, and 12 months
3D Volumetric changes
Time frame: 3, 6, and 12 months
Post-operative pain
Time frame: 14 days after the surgery
Professional esthetic assessment (IDES)
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Implant Complication
Enrolling by invitation
AneuFix - Prophylactic Sac Filling
Abdominal Aortic Aneurysm, Endoleak
Enrolling by invitationObservational study
The General Aim is to Implement Clinical Assessment of Overload by Voluntary Bite Force Registration to Enable Future Simple But Precise Risk Assessment to Provide Individualized Treatment Plans.
Dental Implant, Bruxism
Not yet recruitingObservational study
Linzagolix in Adenomyosis and Recurrent Implantation Failure
Adenomyosis of Uterus, Implantation Failure
RecruitingPhase 4
Comparison Between the Effects of Implantable Gestrinone and Oral Dienogest in the Treatment of Endometriosis
Endometriosis
Active, not recruiting
INTIBIA Pivotal Study
Urinary Incontinence, Urge, Urinary Bladder, Overactive
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lorenzo Tavelli, DDS, MS principal investigator
Harvard School of Dental Medicine, Boston, USA
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vertical soft tissue augmentation in people with Implant Complication, run by Harvard Medical School (HMS and HSDM) at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lorenzo Tavelli, DDS, MS (734-604-4364, lorenzo_tavelli@hsdm.harvard.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Soft tissue dehiscence depth (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2025.